深度学习加速非增强简化肝脏MRI检测恶性局灶性肝病变:双中心验证
这项双中心回顾性研究纳入155例患者,比较深度学习加速非增强简化MRI(AMRIDL)与标准简化MRI(AMRISTD)的图像质量和恶性局灶性病变检出。AMRIDL对恶性局灶性病变的汇总每病灶敏感度为97.6%,与AMRISTD的97.6%相当;在慢性肝病患者中,AMRIDL检测肝细胞癌的每病灶敏感度为96.6%,与AMRISTD的96.5%相似(P>0.05)。AMRIDL在结构锐利度、伪影和噪声方面图像质量更优(均P<0.001),平均扫描时间缩短约50%(2分29秒 vs 4分11秒)。
要点
- AMRIDL对恶性局灶性肝病变的汇总每病灶敏感度为97.6%,与AMRISTD的97.6%相当。
- 慢性肝病患者中AMRIDL检测肝细胞癌的每病灶敏感度为96.6%,与AMRISTD的96.5%相似(P>0.05)。
- AMRIDL在结构锐利度、伪影和噪声方面图像质量均优于AMRISTD(均P<0.001)。
核心结论
- AMRIDL对恶性局灶性病变(包括肝细胞癌)的检出敏感度与AMRISTD相当,同时图像质量显著提升,扫描时间缩短约50%。
研究设计与样本
- 双中心回顾性研究,纳入155例连续患者(110例男性,平均年龄62.4±11岁),均接受标准肝脏MRI及额外AMRIDL序列(DL加速单次激发快速自旋回波SSFSEDL和DL加速扩散加权成像DWIDL)。
关键影像表现/征象
- 体模实验中SSFSEDL的信噪比与SSFSESTD相当,对比噪声比更高;DWIDL与DWISTD的表观扩散系数值相似。
- 155例患者中130例(83.9%)有慢性肝病或肝内外恶性肿瘤病史。
- 64例患者共104个恶性局灶性病变,其中58个(55.8%)为肝细胞癌,38个(36.5%)为转移瘤,4个(3.8%)为胆管癌,4个(3.8%)为淋巴瘤。
诊断标准与关键数值
- 三名阅片者对恶性局灶性病变的汇总每病灶敏感度:AMRIDL为97.6%,AMRISTD为97.6%。
- 慢性肝病患者中检测肝细胞癌的每病灶敏感度:AMRIDL为96.6%,AMRISTD为96.5%(P>0.05)。
- 图像质量采用五分Likert量表评估,AMRIDL在结构锐利度、伪影和噪声方面均优于AMRISTD(均P<0.001)。
临床应用与阅片要点
- 在慢性肝病或恶性肿瘤病史患者中,AMRIDL对恶性局灶性病变(包括肝细胞癌)的检出敏感度与AMRISTD相当。
- AMRIDL可提供更优的结构锐利度、伪影和噪声图像质量,平均扫描时间约2分29秒,较AMRISTD的4分11秒缩短约50%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare a deep learning (DL)-accelerated non-enhanced abbreviated MRI (AMRIDL) protocol with standard AMRI (AMRISTD) of the liver in terms of image quality and malignant focal lesion detection.
MATERIALS AND METHODS: This retrospective study included 155 consecutive patients (110 male; mean age 62.4 ± 11 years) from two sites who underwent standard liver MRI and additional AMRIDL sequences, specifically DL-accelerated single-shot fast-spin echo (SSFSEDL) and DL-accelerated diffusion-weighted imaging (DWIDL). Additional MRI phantom experiments assessed signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and apparent diffusion coefficient (ADC) values. Three reviewers evaluated AMRIDL and AMRISTD protocols for image quality using a five-point Likert scale and identified malignant hepatic lesions. Image quality scores and per-lesion sensitivities were compared between AMRIDL and AMRISTD using the Wilcoxon signed-rank test and logistic regression with generalized estimating equations, respectively.
RESULTS: Phantom experiments demonstrated comparable SNR and higher CNR for SSFSEDL compared to SSFSESTD, with similar ADC values for DWIDL and DWISTD. Among the 155 patients, 130 (83.9%) had chronic liver disease or a history of intra- or extrahepatic malignancy. Of 104 malignant focal lesions in 64 patients, 58 (55.8%) were hepatocellular carcinomas (HCCs), 38 (36.5%) were metastases, four (3.8%) were cholangiocarcinomas, and four (3.8%) were lymphomas. The pooled per-lesion sensitivity across three readers was 97.6% for AMRIDL, comparable to 97.6% for AMRISTD. Compared with AMRISTD, AMRIDL demonstrated superior image quality regarding structural sharpness, artifacts, and noise (all P < 0.001) and reduced the average scan time by approximately 50% (2 min 29 sec vs. 4 min 11 sec). In patients with chronic liver disease, AMRIDL achieved a 96.6% per-lesion sensitivity for HCC detection, similar to 96.5% for AMRISTD (P > 0.05).
CONCLUSION: The AMRIDL protocol offers comparable sensitivity for detecting malignant focal lesions, including HCC while significantly enhancing image quality and reducing scan time by approximately 50% compared to AMRISTD.
引用
- Park SH, Choi MH, Kim B, et al. Deep Learning-Accelerated Non-Contrast Abbreviated Liver MRI for Detecting Malignant Focal Hepatic Lesions: Dual-Center Validation. Korean J Radiol. 2025. PMID: 40150922. doi:10.3348/kjr.2024.0862
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。